Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282143 | 0.87 | MEN1 (0.40) | ALDH1A1MAPK1LMNAFPR2PROKR1 | |
| SCHEMBL1282645 | 0.86 | OPRM1 (0.39) | KDM4EOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL1282238 | 0.86 | OPRM1 (0.39) | KDM4EOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL1282886 | 0.85 | LMNA (0.56) | ALDH1A1MAPK1LMNAPOLBKDM4E | |
| SCHEMBL1282035 | 0.85 | OPRM1 (0.38) | POLBKDM4EOPRM1OPRD1OPRK1 | |
| SCHEMBL1283028 | 0.84 | POLB (0.40) | POLBMEN1KMT2A | |
| SCHEMBL1281858 | 0.84 | KDM4E (0.38) | KDM4EOPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL1282673 | 0.82 | OPRM1 (0.36) | KDM4EMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL1282416 | 0.81 | KDM4E (0.36) | KDM4EMEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL1282057 | 0.81 | CYP3A4 (0.40) | ALDH1A1LMNAFPR2PROKR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2625178-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | Biota Europe Ltd (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | ALDH1A1 2614/4885MAPK1 3226/4885LMNA 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.